agonist

(redirected from Beta agonist)
Also found in: Dictionary, Thesaurus, Medical.

agonist

[′ag·ə‚nist]
(biochemistry)
A chemical substance that can combine with a cell receptor and cause a reaction or create an active site.
(physiology)
A contracting muscle that is resisted or counteracted by another muscle, called an antagonist, with which it is paired.
References in periodicals archive ?
The bronchodilating effect of a beta agonist can be measured on the basis of airflow change, as indicated by, for example, a change in FEV1 or peak expiratory flow rate (PEFR).
"Tiotropium relaxes smooth muscle in the airways through a different mechanism than beta agonists, and thus may help people who do not respond well to currently recommended treatments," said study lead Stephen Peters of Wake Forest University Baptist Medical Center.
Although the risks of single-agent LABAs are well documented, in children and adults, there is not enough information to conclude that "use of the combination mitigates this risk that we know pertains to the long-acting beta agonists," Dr.
Other outcomes included self-reports of morning and evening peak expiratory flow rate, daily use of beta agonists, frequency of nocturnal awakenings, asthma-specific quality of life, as well as change in peripheral blood eosinophil counts.
Another class of drugs, beta agonists, such as albuterol, bitolterol, metaproterenol, pirbuterol, and terbutaline, are used either when the symptoms occur or just before an activity that may cause symptoms.
Shares of Madrigal Pharmaceuticals (MDGL) are sliding in pre-market trading after the company's competitor, Viking Therapeutics (VKTX), announced top-line results from a Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease, or NAFLD, and elevated low-density lipoprotein cholesterol, or LDL-C.
Relvar Ellipta (FF/VI) is the first once-daily, inhaled corticosteroid/long-acting beta agonist (ICS/LABA) combination for the regular treatment of asthma in adults and adolescents aged 12 years and older approved in Japan by the MHLW.
Madrigal Pharmaceuticals (MDGL), down 15% after the company's competitor Viking announced top-line results from a Phase 2 study of its novel liver-selective thyroid receptor beta agonist in patients with non-alcoholic fatty liver disease.
Roth Capital analyst Scott Henry maintained a Buy rating on Viking Therapeutics while raising his price target to $13 from $7.50 saying the data yesterday from Madrigal Pharmaceuticals (MDGL) appears to validate the class of Thyroid Hormone Receptor Beta agonist compounds, noting that Viking's VK2809 is a similar agonist.